Skip to main content

Table 1 Demographic data and clinical characterization of patients enrolled in clinical trial

From: Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial

Group Patient number Age range Sex Co-morbidities RT-PCR at baseline Adverse events Clinical outcome
Control group P1 60–69 2 Hypertension + NO Died
  P2 60–69 2 Diabetes + NO Discharge
  P3 60–69 1 NO + NO Discharge
  P4 60–69 2 NO + NO Discharge
  P5 50–59 2 Hypertension + NO Discharge
  P6 50–59 1 NO + NO Discharge
  P7 60–69 1 NO + NO Discharge
  P8 50–59 2 NO + NO Discharge
  P9 60–69 2 NO + NO Discharge
  P10 60–69 1 Hypertension + NO Discharge
Intervention group P1 50–59 1 Diabetes + Mild headache Died
  P2 60–69 2 NO + Mild headache Discharge
  P3 50–59 1 NO + NO Discharge
  P4 60–69 2 Hypertension + NO Died
  P5 70–79 2 NO + NO Discharge
  P6 60–69 2 Diabetes + NO Discharge
  P7 60–69 2 NO + Mild headache Discharge
  P8 60–69 1 Mild anemia + NO Discharge
  P9 60–69 2 NO + Mild fever Discharge
  P10 50–59 2 NO + NO Discharge
  1. (In gender or sex column, 1 = female and 2 = male)
  2. In this study, the standard care was in accordance with the general treatment protocols approved in that time period and usually included complementary therapies, dexamethasone and remdesivir. Antibiotics and other necessary treatments were also prescribed according to the patient's condition and the physicians' discretion